|
Eton et al
|
3 |
2012 |
USA |
Interviews |
32 (26–85 years) |
Complex patients with chronic diseases and polypharmacy |
Burden of treatment from the perspective of the complex patient |
|
Baylor et al
|
7 |
2007 |
USA |
Interviews |
6 (49–80 years range) |
Spasmodic Dysphonia |
Psychosocial consequences of treatment |
|
Jordan et al
|
8 |
2006 |
UK |
Interviews + structured rating scale and QoL measure |
20 (24–84 years range) |
Long-term percutaneous endoscopic gastrostomies |
Burden of treatment from a patient perspective |
|
Gallacher et al
|
11 |
2011 |
UK |
Secondary analysis of qualitative interview |
47 (45–88 years range) |
Chronic Heart Failure |
Patients’ experiences of treatment burden |
|
Johnston and Noble
|
24 |
2012 |
UK |
Interviews |
9 (74–96 years range) |
Chronic kidney disease |
Burden of treatment and impact on treatment choice |
|
George et al
|
25 |
2010 |
USA |
Interviews |
25 (16–35 years range) |
Cystic Fibrosis |
Barriers and facilitators to treatment adherence |
|
Schofield and Horobin
|
26 |
2014 |
UK |
Interviews |
5.(8–15) |
Primary Ciliary Dyskinesia |
Physiotherapy treatment experiences |
|
Sav et al
|
27 |
2013 |
Australia |
Interviews |
97 (16–83; mean 57.2) |
Chronic conditions |
Treatment burden |
|
Karamandiou et al
|
28 |
2013 |
Greece |
Interviews |
7 (32–68 years) |
End Stage Renal Disease |
Illness beliefs, treatment experiences and adherence |
|
Fried and Bradley
|
29 |
2003 |
USA |
Focus groups and interviews |
23 (mean age of 70 years) |
Congestive heart failure, chronic obstructive pulmonary disease, or cancer with limited life expectancy |
End-of-Life treatment decisions |
|
Lewis and Newell
|
30 |
2009 |
Nepal |
Interviews and Focus groups |
23 (age not stated) |
Tuberculosis |
Improving care and understanding patient support |
